Parabilis Medicines officer reports option holdings
Parabilis Medicines, Inc. officer Rohin Mhatre filed an initial Form 3 reporting holdings of stock options to purchase the company’s common stock.
Rhea-AI Filing Summary
Parabilis Medicines, Inc. officer Rohin Mhatre filed an initial Form 3 reporting holdings of stock options to purchase the company’s common stock. The filing lists three option grants with different exercise prices, share amounts and expiration dates.
One option covers 243,680 underlying shares at an exercise price of $3.14 per share expiring on February 17, 2036. Two additional options cover 181,948 and 38,988 underlying shares at an exercise price of $1.48 per share, both expiring on March 27, 2034. Footnotes explain that these options vest in monthly installments over multi‑year periods, contingent on continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Mhatre Rohin
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 464,616 contracts (Direct)
Footnotes (3)
- F1. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from January 1, 2024, subject to the Reporting Person's continued service on each such vesting date.
- F2. 25% of the shares subject to this option vested and became exercisable on October 23, 2024 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- F3. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 9, 2026, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Option underlying shares: 243,680 shares
Exercise price: $3.14 per share
Option underlying shares: 181,948 shares
+3 more
6 metrics
Option underlying shares
243,680 shares
Underlying common stock for option at $3.14 exercise price
Exercise price
$3.14 per share
Stock option on 243,680 underlying shares
Option underlying shares
181,948 shares
Underlying common stock for option at $1.48 exercise price
Option underlying shares
38,988 shares
Underlying common stock for option at $1.48 exercise price
Expiration date
February 17, 2036
Expiration for $3.14 stock option grant
Expiration date
March 27, 2034
Expiration for $1.48 stock option grants
Key Terms
Stock Option (right to buy), underlying security, exercise price, vesting
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
underlying security financial
"underlying_security_title: Common Stock"
exercise price financial
"conversion_or_exercise_price: 3.1400 and 1.4800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares subject to this option shall vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Parabilis Medicines (PBLS) disclose in Rohin Mhatre’s Form 3?
Parabilis Medicines reports that officer Rohin Mhatre holds three stock option awards for its common stock. The Form 3 lists each option’s exercise price, number of underlying shares, expiration dates and vesting schedules tied to his continued service with the company.
What are the exercise prices of Rohin Mhatre’s Parabilis Medicines (PBLS) options?
Mhatre’s disclosed options have exercise prices of $3.14 and $1.48 per share. The largest grant is priced at $3.14, while two additional grants are priced at $1.48, providing different potential entry levels if exercised in the future.
When do Rohin Mhatre’s Parabilis Medicines (PBLS) options expire?
The option covering 243,680 underlying shares expires on February 17, 2036. The options covering 181,948 and 38,988 underlying shares each expire on March 27, 2034, giving long-dated potential for exercise if vesting and service conditions are met.
How do Rohin Mhatre’s Parabilis Medicines (PBLS) options vest?
Footnotes state some options vest in forty-eight equal monthly installments starting on specific dates, while another vests 25% at an initial date, then in thirty-six monthly installments. All vesting depends on Mhatre’s continued service with Parabilis Medicines on each vesting date.
Does Parabilis Medicines (PBLS) Form 3 show any recent insider buying or selling?
The Form 3 lists option holdings but does not report open‑market purchases or sales. Transactions are classified as holdings, with no buy or sell transaction codes indicated, so the filing mainly establishes Mhatre’s existing derivative positions in company stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
